Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16759116rdf:typepubmed:Citationlld:pubmed
pubmed-article:16759116lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0026457lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0444669lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:16759116lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:16759116pubmed:issue12lld:pubmed
pubmed-article:16759116pubmed:dateCreated2006-6-8lld:pubmed
pubmed-article:16759116pubmed:abstractTextThe synthesis and enzyme inhibitor properties of reversible type B monoamine oxidase inhibitors are described. These compounds belong to the 5H-indeno[1,2-c]pyridazine family and possess a hydrophobic benzyloxy or 4,4,4-trifluorobutoxy side chain which, in contrast to a previous assignment, has been unambiguously located at C(8) of the heterocyclic moiety. Investigation of the regioisomeric structures establishes that substitution of the 5H-indeno[1,2-c]pyridazin-5-one core at C(7) vs C(8) dramatically influences the MAO-inhibiting properties of these compounds.lld:pubmed
pubmed-article:16759116pubmed:languageenglld:pubmed
pubmed-article:16759116pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16759116pubmed:citationSubsetIMlld:pubmed
pubmed-article:16759116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16759116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16759116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16759116pubmed:statusMEDLINElld:pubmed
pubmed-article:16759116pubmed:monthJunlld:pubmed
pubmed-article:16759116pubmed:issn0022-2623lld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:WoutersJohanJlld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:OomsFrédéricFlld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:KriefAlainAlld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:FrédérickRaph...lld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:CastagnoliNea...lld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:Van der...lld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:DumontWillyWlld:pubmed
pubmed-article:16759116pubmed:authorpubmed-author:AschenbachLin...lld:pubmed
pubmed-article:16759116pubmed:issnTypePrintlld:pubmed
pubmed-article:16759116pubmed:day15lld:pubmed
pubmed-article:16759116pubmed:volume49lld:pubmed
pubmed-article:16759116pubmed:ownerNLMlld:pubmed
pubmed-article:16759116pubmed:authorsCompleteYlld:pubmed
pubmed-article:16759116pubmed:pagination3743-7lld:pubmed
pubmed-article:16759116pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:meshHeadingpubmed-meshheading:16759116...lld:pubmed
pubmed-article:16759116pubmed:year2006lld:pubmed
pubmed-article:16759116pubmed:articleTitleSynthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core.lld:pubmed
pubmed-article:16759116pubmed:affiliationLaboratoire de Chimie Biologique Structurale, Drug Design and Discovery Center, Facultés Universitaires N.D de la Paix, 61 rue de Bruxelles, B-5000 Namur, Belgium.lld:pubmed
pubmed-article:16759116pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16759116pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16759116lld:chembl